{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:35:26Z","timestamp":1782218126518,"version":"3.54.5"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the safety and effectiveness of iGlarLixi in people with type 2 diabetes mellitus (T2DM) in clinical practice in Mexico.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This was a prospective, observational, multicentre study in adults with T2DM who were prescribed iGlarLixi in routine clinical practice in Mexico. The participants were followed for 24\u2009\u00b1\u20091\u2009months. The primary endpoint included the incidence proportion, incidence rate of adverse drug reactions (ADRs), serious ADRs and the severity of suspected ADRs possibly related to iGlarLixi throughout the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 330 participants (mean\u2009\u00b1\u2009SD age: 57.8\u2009\u00b1\u200911.9\u2009years, weight: 77.1\u2009\u00b1\u200917.7\u2009kg, duration of diabetes: 14.1\u2009\u00b1\u20099.9\u2009years, and female: 55.5%). During the 24\u2010month study, 59 participants (17.9%; 95% confidence interval [CI]: 13.9\u201322.4) reported 95 ADRs, with a mean of 0.164 events per participant\u2010year. The most commonly reported ADRs were gastrointestinal disorders (11.2%), with nausea being the most frequent (7.3%). HbA1c decreased from 9.5% at baseline to 7.3% at the end of the study. Additionally, 51.7%, 64.6% and 86.3% of participants achieved the glycaemic target of HbA1c\u2009&lt;\u20097%, FPG &lt;\u2009110\u2009mg\/dL and PPG &lt;\u2009180\u2009mg\/dL, respectively, at the end of the study. A significant decrease (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) in 7\u2010point self\u2010monitoring plasma or capillary blood glucose was observed from baseline to 3, 6, 12 and 24 months post iGlarLixi initiation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>iGlarLixi demonstrated a consistent safety profile aligned with findings from previous randomised controlled trials. The most common ADRs were gastrointestinal disorders that were generally tolerable. Over 50% of participants treated with iGlarLixi achieved their glycaemic targets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.16357","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T08:53:00Z","timestamp":1743843180000},"page":"3389-3396","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and clinical effectiveness of\n                    <scp>iGlarLixi<\/scp>\n                    in people with type 2 diabetes mellitus in Mexico"],"prefix":"10.1111","volume":"27","author":[{"given":"Juan","family":"Rosas\u2010Guzman","sequence":"first","affiliation":[{"name":"Centro de Especialidades M\u00e9dicas de Celaya  Celaya Guanajuato Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Navarro\u2010Lara","sequence":"additional","affiliation":[{"name":"Consultorio de Medicina Especializada del Sector Privado  Tijuana Baja California Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8463-462X","authenticated-orcid":false,"given":"Maria Elena","family":"Sa\u00f1udo\u2010Maury","sequence":"additional","affiliation":[{"name":"Sanofi  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8301-4134","authenticated-orcid":false,"given":"Luis","family":"Anguiano","sequence":"additional","affiliation":[{"name":"Sanofi  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leobardo","family":"Sauque\u2010Reyna","sequence":"additional","affiliation":[{"name":"Instituto de Diabetes Obesidad y Nutricion S.C  Cuernavaca Morelos Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"Diabetes Atlas","author":"International Diabetes Federation","year":"2021"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1368980013000086"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2024.04.010"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15797"},{"issue":"6","key":"e_1_2_10_6_1","article-title":"Glycemic control for type 2 diabetes mellitus patients: a systematic review","volume":"14","author":"Rakhis Sr SAB","year":"2022","journal-title":"Cureus"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/ds20-0097"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S006"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/cd18-0091"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017717281"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15125"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0393"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01128-5"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16\u20100917"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-er06d"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0547-5"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14139"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1357"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01407-3"},{"key":"e_1_2_10_20_1","unstructured":"Diario Oficial de la Federaci\u00f3n.NORMA Oficial Mexicana NOM\u2010015\u2010SSA2\u20102010 Para la prevenci\u00f3n tratamiento y control de la diabetes mellitus.https:\/\/www.dof.gob.mx\/normasOficiales\/4215\/salud\/salud.htm"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14822"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06314-9"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0296343"},{"issue":"10","key":"e_1_2_10_24_1","article-title":"Effect of lockdown on diabetes care during the COVID\u201019 pandemic: result of a telephone\u2010based survey among patients attending a diabetic Clinic in Northern India","volume":"13","author":"Verma M","year":"2021","journal-title":"Cureus"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.16357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:56:06Z","timestamp":1761893766000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.16357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/dom.16357"],"URL":"https:\/\/doi.org\/10.1111\/dom.16357","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.16357\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16357\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16357\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16357\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16357\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16357\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16357\/v1\/review1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"2024-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}